

# OPIOID MANAGER

The Opioid Manager is designed to be used as a point of care tool for providers prescribing opioids for chronic non cancer pain. It condenses key elements from the Canadian Opioid Guideline and can be used as a chart insert.

## A Before You Write the First Script

Patient Name: \_\_\_\_\_

Pain Diagnosis: \_\_\_\_\_

Date of Onset: \_\_\_\_\_

### Goals decided with patient:

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

### Initiation Checklist

	Y	N	Date
Are opioids indicated for this pain condition			
Explained potential benefits			
Explained adverse effects			
Explained risks			
Patient given information sheet			
Signed treatment agreement (as needed)			
Urine drug screening (as needed)			

### Opioid Risk Tool

By Lynn R. Webster MD

Item (circle all that apply)	Item score if female	Item score if male
<b>1. Family History of Substance Abuse:</b>		
Alcohol	1	3
Illegal Drugs	2	3
Prescription Drugs	4	4
<b>2. Personal History of Substance Abuse:</b>		
Alcohol	3	3
Illegal Drugs	4	4
Prescription Drugs	5	5
<b>3. Age (mark box if 16-45)</b>		
	1	1
<b>4. History of Preadolescent Sexual Abuse</b>		
	3	0
<b>5. Psychological Disease</b>		
Attention Deficit Disorder, Obsessive-Compulsive Disorder, or Bipolar, Schizophrenia	2	2
Depression	1	1
<b>Total</b>		
<b>Total Score Risk Category:</b>		
Low Risk: 0 to 3, Moderate Risk: 4 to 7, High Risk: 8 and above		

### Overdose Risk

#### Patient Factors

- Elderly
- On benzodiazepines
- Renal impairment
- Hepatic impairment
- COPD
- Sleep apnea
- Sleep disorders
- Cognitive impairment

#### Provider Factors

- Incomplete assessments
- Rapid titration
- Combining opioids and sedating drugs
- Failure to monitor dosing
- Insufficient information given to patient and/or relatives

#### Opioid Factors


- Codeine & Tramadol - lower risk
- CR formulations - higher doses than IR

#### Prevention

- Assess for Risk Factors
- Educate patients /families about risks & prevention

- Start low, titrate gradually, monitor frequently
- Careful with benzodiazepines
- Higher risk of overdose - reduce initial dose by 50%; titrate gradually
- Avoid parenteral routes
- Adolescents; elderly - may need consultation
- Watch for Misuse

### Stepped Approach to Opioid Selection



## B Initiation Trial

A closely monitored trial of opioid therapy is recommended before deciding whether a patient is prescribed opioids for long term use.

**Suggested Initial Dose and Titration** (Modified from Weaver M., 2007 and the e-CPS, 2008) Notes: The table is based on oral dosing for CNCP. Brand names are shown if there are some distinct features about specific formulations. Reference to brand names as examples does not imply endorsement of any of these products. CR = controlled release, IR = immediate release, NA = not applicable, ASA: Acetylsalicylic Acid

Opioid	Initial dose	Minimum time interval for increase	Suggested dose increase	Minimum daily dose before converting IR to CR
Codeine (alone or in combination with acetaminophen or ASA)	15-30 mg q.4 h. as required	7 days	15-30 mg/day up to maximum of 600 mg/day (acetaminophen dose should not exceed 3.2 grams/day)	100 mg
CR Codeine	50 mg q.12 h.	2 days	50 mg/day up to maximum of 300 mg q.12 h.	NA
Tramadol (37.5 mg) + acetaminophen (325 mg)	1 tablet q.4-6 h. as needed up to 4/day	7 days	1-2 tab q. 4-6 h. as needed up to maximum 8 tablets/day	3 tablets
CR Tramadol	a) Zytrom XL®: 150 mg q. 24 h. b) Tridural™: 100 mg q. 24 h. c) Ralivia™: 100 mg q. 24 h.	a) 7 days b) 2 days c) 5 days	Maximum doses: a) 400 mg/day b) 300 mg/day c) 300 mg/day	NA
IR Morphine	5-10 mg q. 4 h. as needed maximum 40 mg/day	7 days	5-10 mg/day	20-30 mg
CR Morphine	10-30 mg q.12 h. Kadian®: q.24 h. Kadian® should not be started in opioid-naïve patients	Minimum 2 days, recommended: 14 days	5-10 mg/day	NA
IR Oxycodone	5-10 mg q. 6 h. as needed maximum 30 mg/day	7 days	5 mg/day	20 mg
CR Oxycodone	10-20 mg q.12 h. maximum 30 mg/day	Minimum 2 days, recommended: 14 days	10 mg/day	NA
IR Hydromorphone	1-2 mg q. 4-6 h. as needed maximum 8 mg/day	7 days	1-2 mg/day	6 mg
CR Hydromorphone	3 mg q. 12 h. maximum 9 mg/day	Minimum 2 days, recommended: 14 days	2-4 mg/day	NA

### Initiation Trial Chart

Date	D/M/Y	D/M/Y	D/M/Y	D/M/Y
Opioid prescribed				
Daily dose				
Daily morphine equivalent				
More than 200				
Less than 200				
Goals achieved → Yes, No, Partially				
Pain intensity				
Functional status → Improved, No Change, Worsened				
Adverse effects				
Nausea				
Constipation				
Drowsiness				
Dizziness/Vertigo				
Dry skin/Pruritis				
Vomiting				
Other?				
Complications? (Reviewed: Y/N)				
Aberrant Behaviour (Reviewed: Y/N)				
Urine Drug Screening (Y/N)				
Other Medications				

0 = None  
1 = Limits ADLs  
2 = Prevents ADLs

Watchful Dose > than 200

To access the Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-cancer Pain and to download the Opioid Manager visit <http://nationalpaincentre.mcmaster.ca/opioid/>

**Morphine Equivalence Table**

Opioid	Equivalent Doses (mg)	Conversion to MEQ
Morphine	30	1
Codeine	200	0.15
Oxycodone	20	1.5
Hydromorphone	6	5
Meperidine	300	0.1
Methadone & Tramadol	Dose Equivalents unreliable	
Transdermal fentanyl	60 – 134 mg morphine = 25 mcg/h 135 – 179 mg = 37 mcg/h 180 – 224 mg = 50 mcg/h 225 – 269 mg = 62 mcg/h 270 – 314 mg = 75 mcg/h 315 – 359 mg = 87 mcg/h 360 – 404 mg = 100 mcg/h	
<b>Switching Opioids:</b>		
<b>If previous opioid dose was:</b>	<b>Then, SUGGESTED new opioid dose is:</b>	
<b>High</b>	50% or less of previous opioid (converted to morphine equivalent)	
<b>Moderate or low</b>	60-75% of the previous opioid (converted to morphine equivalent)	

**Maintenance & Monitoring Chart**

Date	D / M / Y	D / M / Y	D / M / Y	D / M / Y	D / M / Y	D / M / Y
Opioid prescribed						
Daily dose						
Daily morphine equivalent						
More than 200						
Less than 200						
Goals achieved → Yes, No, Partially						
Pain intensity						
Functional status → Improved, No Change, Worsened						
Adverse effects						
Nausea						
Constipation						
Drowsiness						
Dizziness/Vertigo						
Dry skin/Pruritis						
Vomiting						
Other?						
Complications? (Reviewed: Y/N)						
Aberrant Behaviour (Reviewed: Y/N)						
Urine Drug Screening (Y/N)						
Other Medications						

0 = None  
1 = Limits ADLs  
2 = Prevents ADLs

Watchful Dose > than 200

**When is it time to Decrease the dose or Stop the Opioid completely?**

When to stop opioids	Examples and Considerations
<b>Pain Condition Resolved</b>	Patient receives definitive treatment for condition. A trial of tapering is warranted to determine if the original pain condition has resolved.
<b>Risks Outweighs Benefits</b>	Overdose risk has increased. Clear evidence of diversion. Aberrant drug related behaviours have become apparent.
<b>Adverse Effects Outweighs Benefits</b>	Adverse effects impairs functioning below baseline level. Patient does not tolerate adverse effects.
<b>Medical Complications</b>	Medical complications have arisen (e.g. hypogonadism, sleep apnea, opioid induced hyperalgesia)
<b>Opioid Not Effective</b>	<b>Opioid effectiveness = improved function or at least 30% reduction in pain intensity</b> Pain and function remains unresponsive. Opioid being used to regulate mood rather than pain control. Periodic dose tapering or cessation of therapy should be considered to confirm opioid therapy effectiveness.

**How to Stop – the essentials**

**How do I stop?** The opioid should be tapered rather than abruptly discontinued.

**How long will it take to stop the opioid?** Tapers can usually be completed between 2 weeks to 4 months.

**When do I need to be more cautious when tapering? Pregnancy:** Severe, acute opioid withdrawal has been associated with premature labour and spontaneous abortion.

**How do I decrease the dose?** Decrease the dose by no more than 10% of the total daily dose every 1-2 weeks. Once one-third of the original dose is reached, decrease by 5% every 2-4 weeks. Avoid sedative-hypnotic drugs, especially benzodiazepines, during the taper.

**Aberrant Drug Related Behaviour** (Modified by Passik, Kirsh et al 2002).

Indicator	Examples
*Altering the route of delivery	• Injecting, biting or crushing oral formulations
*Accessing opioids from other sources	• Taking the drug from friends or relatives • Purchasing the drug from the "street" • Double-doctoring
Unsanctioned use	• Multiple unauthorized dose escalations • Binge rather than scheduled use
Drug seeking	• Recurrent prescription losses • Aggressive complaining about the need for higher doses • Harassing staff for faxed scripts or fit-in appointments • Nothing else "works"
Repeated withdrawal symptoms	• Marked dysphoria, myalgias, GI symptoms, craving
Accompanying conditions	• Currently addicted to alcohol, cocaine, cannabis or other drugs • Underlying mood or anxiety disorders not responsive to treatment
Social features	• Deteriorating or poor social function • Concern expressed by family members
Views on the opioid medication	• Sometimes acknowledges being addicted • Strong resistance to tapering or switching opioids • May admit to mood-leveling effect • May acknowledge distressing withdrawal symptoms

★ = behaviours more indicative of addiction than the others.